Final Report of a Phase I Trial of Olaparib with Cetuximab and Radiation for Heavy Smoker Patients with Locally Advanced Head and Neck Cancer

PURPOSE: Our goal was to evaluate the safety and toxicity of combining a PARP inhibitor, olaparib, with cetuximab and fractionated intensity-modulated radiotherapy for patients with locally advanced head and neck cancer and heavy smoking histories. PATIENTS AND METHODS: Patients with ≥10 packs/year...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Karam, Sana D., Reddy, Krishna, Blatchford, Patrick J., Waxweiler, Tim, DeLouize, Alicia M., Oweida, Ayman, Somerset, Hilary, Marshall, Carrie, Young, Christian, Davies, Kurtis D., Kane, Madeleine, Tan, Aik Choo, Wang, Xiao Jing, Jimeno, Antonio, Aisner, Dara L., Bowles, Daniel W., Raben, David
Formato: Artigo
Idioma:Inglês
Publicado em: 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6873707/
https://ncbi.nlm.nih.gov/pubmed/30084837
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-18-0467
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados